Alembic's Methotrexate Sodium ANDA217552 Receives AP Status from FDA
Alembic's application for Methotrexate Sodium has received an Abbreviated Approval (AP) status from the FDA.
Asset / Drug
Drug and asset intelligence for Alembic with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Chemotherapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.